Drew E. Lewis
Impact in
- Molecular Medicine top 2%
- Antibiotic Resistance in Bacteria
-
- Antibiotic Use and Resistance
Papers in
-
- Antibiotic Resistance in Bacteria 5
-
- Antibiotic Use and Resistance 3
- Co-authors
- Jeanne D. Breen (2 shared papers)David Altarac (5 shared papers)Alita A. Miller (4 shared papers)Khurram Z. Rana (5 shared papers)Lan Chen (1 shared paper)Bin Du (1 shared paper)Andrew F. Shorr (1 shared paper)Richard G. Wunderink (1 shared paper)
- Journals
- Open Forum Infectious Diseases (4 papers)The Lancet Infectious Diseases (1 paper)CHEST Journal (1 paper)Molecular Genetics and Metabolism (1 paper)Antimicrobial Agents and Chemotherapy (1 paper)
- Partner nations
- United StatesPeruChina
In The Last Decade
Drew E. Lewis
11 papers receiving 347 citations
Drew E. Lewis's Hit Papers
Peers
Comparison fields: 5 of 42
- Molecular Medicine 187
- Applied Microbiology and Biotechnology 58
- Endocrinology 29
- Pharmacology 79
- Epidemiology 117
Countries citing papers authored by Drew E. Lewis
This map shows the geographic impact of Drew E. Lewis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Drew E. Lewis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Drew E. Lewis more than expected).
Fields of papers citing papers by Drew E. Lewis
This network shows the impact of papers produced by Drew E. Lewis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Drew E. Lewis. The network helps show where Drew E. Lewis may publish in the future.
Co-authors
The 25 scholars most cited alongside Drew E. Lewis, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Efficacy and safety of sulbactam–durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii–calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK) Hit paper breakdown → | 2023 | 222 |
| 2 | 2005 | 62 | |
| 3 | 2005 | 58 | |
| 4 | 2025 | 11 | |
| 5 | 2010 | 7 | |
| 6 | 2021 | 7 | |
| 7 | 2022 | 3 | |
| 8 | 2022 | 1 | |
| 9 | 2022 | 1 | |
| 10 | 2022 | 1 | |
| 11 | 2015 | 1 |
About Drew E. Lewis
Drew E. Lewis is a scholar working on Molecular Medicine, Applied Microbiology and Biotechnology, Pharmacology, Microbiology and Epidemiology, having authored 11 papers that have together received 374 indexed citations. Recurring topics across this work include Antibiotic Resistance in Bacteria (5 papers), Antibiotics Pharmacokinetics and Efficacy (4 papers), Antibiotic Use and Resistance (3 papers), Respiratory viral infections research (2 papers), Pneumonia and Respiratory Infections (2 papers), Berberine and alkaloids research (1 paper), Lysosomal Storage Disorders Research (1 paper) and Glycosylation and Glycoproteins Research (1 paper). The work is most often cited by research in Molecular Medicine (187 citations), Applied Microbiology and Biotechnology (58 citations), Endocrinology (29 citations), Pharmacology (79 citations) and Epidemiology (117 citations). Drew E. Lewis has collaborated with scholars based in United States, Peru and China. Frequent co-authors include Jeanne D. Breen, David Altarac, Alita A. Miller, Khurram Z. Rana, Lan Chen, Bin Du, Andrew F. Shorr, Richard G. Wunderink, John P. O’Donnell and Robin Isaacs. Their work appears in journals such as Open Forum Infectious Diseases, The Lancet Infectious Diseases, CHEST Journal, Molecular Genetics and Metabolism and Antimicrobial Agents and Chemotherapy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.